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At the outset, we would like to point out several limitations in this study. It was collected from a hospital and from a single department of vascular surgery. There was a significant loss of information as it was a retrospective study. The data were analyzed to present a picture of what had been seen. The prevalence of SVT was not recorded for arterial cases and in cases which were induced by intravenous (IV) catheters. These are common causes for SVT. [5] The authors would like to take this opportunity to point out the importance of recording even such "trivial" details into the patients' medical record. It is the authors' subjective experience that most cases of IV catheter-induced SVT remain undocumented and, hence, lost to understanding. This showcases the widespread hold of the "benign" understanding of SVT, which the authors aim to change.
The demographic data and imaging data, management, and follow-up data were collected from the hospital records. The data were entered into EpiData software [6] , and Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA), and data analysis was done in R (version 3.5.0) [7] and Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA).
RESULTS
There were a total of 117 patients, 82 (72.65%) men and 35 (27.35%) women, between the ages of 16 and 76 years.
The mean age was 45.33 ± 14.12 years. There were no cases of upper-limb SVT in our series.
All patients were divided into two groups on the basis of their clinical presentation and initial line of management -the first group was patients presenting with acute SVT (SVT-only group) and the second group who primarily presented with DVT but also found to have SVT (SVT and DVT group). In addition, a patient was noted to have "clinical" diagnosis when there was a clinical suspicion of SVT which was confirmed with a compression duplex ultrasound scan. An "imaging" diagnosis was when the patient was found to have SVT on imaging for either DVT or varicose veins with no clinical suspicion of the same. The details of these groups are summarized in Table 1 .
Seventy-seven (65.8%) patients were associated with the presence of varicose veins. Twenty-three (19.7%) patients had a prior history of thromboembolic disease. Six patients had suspected prothrombotic conditions. Three of the six patients had hyperhomocysteinemia. Among the other three patients, two patients had a past history of recurrent DVT and the third patient had a history of prior mesenteric ischemia. Although a prothrombotic state was suspected based on exclusion, a full workup could not be done due to financial reasons.
Malignancy was suspected to be the cause in three patients. One was a female who had been diagnosed to have acute leukemia. The second was a female who presented with recurrent migratory SVT. On evaluation, she was found to have a bulky uterus. However, the pathology report after hysterectomy did not show any evidence of malignancy. Despite this, she was also put into this category as the clinical presentation can be best explained by an occult malignancy. The third was a female with multiple uterine fibroids. She also underwent a hysterectomy which was also reported as benign.
Among patients with infection as the suspected cause of the venous thrombosis, three patients presented with cellulitis, one patient had underlying chronic osteomyelitis, and one patient had ulcers on the leg. Nicotine exposure was seen in four patients. However, they did not have any concomitant arterial disease. Other risk factors are described in Table 2 .
Fifty-three (45.4%) patients received anticoagulation in some form. A patient was counted as having received anticoagulation if he had received the drug for at least 4 weeks. The choice of anticoagulant was decided by the treating physician based on comorbid illnesses of the patient and its affordability. In case of Vitamin K antagonists (VKAs), the target international normalized ratio was kept at 2-3. With the advent and rise of the newer oral anticoagulants, they were used in patients in lieu of VKAs due to the ease of their dosing and lack of monitoring requirement. However, this was a very individualized decision made on a case-by-case basis. The most common class of drug used was the oral VKAs. The different anticoagulants used and the duration are shown in Tables 3 and 4 . The use of low-molecular-weight heparin (LMWH)/fondaparinux was not seen in our sample. The duration of anticoagulation for each patient was decided by the treating physician. It has been our protocol that all patients with thrombosis are advised anticoagulation for a period of 3 months. In cases who also have a concurrent DVT, a low D-dimer was used as a marker to indicate cessation of active thrombotic activity. Only one patient, a 76-year-old female, with acute leukemia, from Group 2 did not receive anticoagulation as per her decision. All of the patients received anti-inflammatory drugs and analgesics. The local symptoms improved significantly, but some patients developed thromboembolic complications.
Six patients developed systemic venous thromboembolic complications.
In the group with SVT only, three patients had PE and one patient had DVT. The first was a 66-year-old male who had presented with thrombus involving the proximal great saphenous vein (GSV). He underwent immediate ligation of the saphenofemoral junction (SFJ) and did not receive any long-term postoperative anticoagulation. The second was a 51-year-old female who had earlier presented with multiple episodes of migratory SVT. The third was a 48-year-old male who had presented earlier with recurrent DVT. He presented with acute isolated SVT and progressed to develop PE on anticoagulation.
From the second group, two patients had PE and two patients developed recurrent DVT. In this group, it is unclear if these complications are secondary to the SVT or the DVT.
diScUSSiOn
The exact incidence of SVT is unclear, but it is more common in older people and in women. [8] [9] [10] [11] A large population study done in France showed that the incidence of lower-limb SVT is 0.64% per person-year in an adult population. [12] The most common veins involved include the great and short saphenous veins and their tributaries. [4] Group 1 in our study was predominantly men (70.58%) as compared to a study from Spain which had 60% women. [13] The risk factors for this condition seen in our population are similar to those found in studies from other countries around the world. [13] In our study, only 54.12% of patients in Group 1 received anticoagulation. This is low compared to the Prospective Epidemiological Multicenter Cohort Study on Patients Clinically Suspected of Deep Vein Thrombosis or Pulmonary Embolism (OPTIMEV) study, in which 75% of patients received anticoagulation. [14] In patients with SVT only, 3/85 (3.5%) had PE. This is similar to other studies which have reported a range from 1.9% to 13.3%. [9, 12, 15] It has to be kept in mind that every patient in our series was not screened for PE.
Awareness of the importance of SVT is extremely important in its proper treatment. Over the past 10 years, the awareness has improved at our center.
Previous episodes of SVT with or without DVT increase the risk of subsequent SVT, but varicose veins remain the most common (88%) and clinically important etiological factor for SVT. A diagnosis of SVT should always prompt a search for varicose veins and should be treated if present. [16] In patients without cancer, an episode of isolated SVT was found to increase the risk of subsequent superficial venous thrombosis. [2] It can be intuitively extrapolated that, in a patient with DVT, the chance of the thrombus extending into the superficial veins is quite high. In a patient who is found to have both SVT and DVT concurrently, it stands to debate as to which was the primary inciting factor. Although the immediate line of management would not be different, this differentiation may play an important role in evaluating potential etiology of the condition as well to aid in understanding the natural history of these life-threatening disorders. Hence, the authors feel it imperative to stress on the fact that isolated acute SVT should be treated appropriately and should be evaluated on par with a DVT.
In addition, in patients with clinical suspicion or diagnosed with DVT, it would help to proactively look for a superficial vein thrombosis and to document the same. The presence of a residual thrombus in the superficial vein after recanalization of the deep veins could be an inciting factor for recurrent venous thromboembolism (VTE) after completion of anticoagulation course in these patients.
Thromboangiitis obliterans (TAO) is a chronic inflammatory nonatherosclerotic thrombotic disorder of the medium-and small-sized arteries, commonly associated with smoking/ tobacco consumption. SVT seen in the background of TAO has a different clinical course and treatment is primarily directed toward the arterial component. [3] 
Risk factors
The myriad of risk factors involved in SVT can be broadly classified into three groups based on the Virchow's triad, as shown in Table 5 . [3] Classification SVT can be classified based on the presence or absence of varicose veins as varicose vein SVT and nonvaricose SVT (NV-SVT) [ Table 6 ]. [3, 5] It can also be classified as primary or secondary. Primary SVT is when the thrombotic process involves only the affected vessels. Secondary SVT is when it occurs in the background of systemic inflammatory processes. [5] 
Diagnosis
Diagnosis of SVT is essentially clinical and is based on the findings of pain, tenderness, erythema, or induration overlying one or more superficial veins with or without fever and leukocytosis. [1, 3] The acute symptoms last for up to 3 weeks following which either fibrosis or recanalization of the vein occurs. This process could take up to 8 weeks. [3] Complications 24%-29% of patients diagnosed with SVT have been found to have a concurrent, mostly asymptomatic DVT. Age >75 years, active cancer, ongoing hospital admission, and SVT on NV veins were found to be significant and independent risk factors for the same. This DVT could also be on the contralateral limb, and hence, a comprehensive duplex ultrasound of both lower limbs should be done in all patients with SVT. [15, 17] In a study by van Langevelde et al., patients with a previously diagnosed SVT had the risk of DVT and PE six times and four times higher than an age-matched control with no prior history of SVT. [2] In patients diagnosed with isolated SVT without cancer, there was a 5.4% chance of recurrence of thromboembolic events every year and nearly half of them were recurrent SVT. [14] Other complications include skin hyperpigmentation, local soft-tissue infection, and abscess formation. [1] Management Based on the current guidelines, a proposed algorithm for management has been depicted in Figure 1 . Investigations in a patient with superficial thrombophlebitis are aimed at two possible goals: 1. To delineate the anatomy of the thrombosis and to rule out deep vein involvement a. Duplex ultrasound -a combination of B mode ultrasound and Doppler evaluation. It is the initial investigation of choice due to its noninvasive and inexpensive nature [3] b. If concomitant varicose veins are noted, a formal venous duplex should be performed and further treatment should be planned for the varicose veins. 2. To identify the cause of the thrombophlebitis [3] a. Test for acquired or congenital hypercoagulable states -most common ones include factor V Leiden mutation (16%); prothrombin G mutation (10%); and deficiencies in antithrombin III, protein C, or protein S (10%). [1] These conditions should be checked for in any patients following the exclusion of varicose veins, autoimmune disease, and malignancy. [18] Conditions that could be checked for include thrombin time, functional antithrombin level, clotting protein C and protein S assays, free protein S, activated protein C resistance, factor V Leiden, G20210A prothrombin gene mutation, C677T MTHFR gene mutation, FVIII levels, lupus anticoagulant, anticardiolipin and anti-beta 2 glycoprotein-I antibodies, and fasting plasma homocysteine levels. [13] b. Malignancies -In a study by Mouton et al., 12. 9% of patients with SVT had an underlying malignancy. [19] Imaging should be directed toward identifying the primary malignancy. SVT is most commonly seen associated with adenocarcinoma of pancreas, carcinoma colon, breast malignancies, hematological malignancies, and skin cancer. [1, 19] Role of serial duplex ultrasonography -There are no studies at present to clarify the exact timing and frequency of serial duplex ultrasound in patients who have been diagnosed with superficial vein thrombosis.
Role of D-dimer
D-dimer assay can be used to exclude DVT and PE. However, in patients with SVT, a positive assay was seen in only 68% of patients. This was not affected by the presence of varicose veins. Beyond a threshold thrombus volume of 5914 m 3 , all D-dimer tests were positive. Even though the sensitivity was at 100%, the sensitivity was only 29% (95% confidence interval: 19%-42%). [20] In a study of only upper-extremity SVT, D-dimer cutoff of <500 ng/ml was found to have a negative predictive value of 93% with a sensitivity of 77% and a specificity of 60%. [21] Furthermore, D-dimer is a nonspecific test and does not help differentiate SVT from DVT or PE. [1] However, D-dimer may have a role in the follow-up of SVT and to determine the duration of anticoagulation therapy. The PROLONG study suggests that anticoagulation may be safely stopped in patients with low D-dimer at 1 month following the index thrombotic event. [22, 23] If the peripheral pulses are absent, further investigations should proceed in the evaluation of the arterial system.
Treatment
All therapies [ Table 7 ] should aim to achieve the following goals: [1, 3] 1. To decrease the acute symptoms, namely pain and erythema 2. To prevent potential complications -local infection/DVT/ PE/extension of SVT/recurrence of SVT.
The mainstay of treatment of all types of SVT is anticoagulation supplemented with nonsteroidal anti-inflammatory drugs (oral/ topical), gentle compression, and mobilization as tolerated. [5] Antibiotics are also added in patients who have evidence of local infection. [1] In cases of acute SVT with erythema and swelling of the lower limb, the patient was given limb elevation, local magnesium sulfate application (to reduce the edema), and bed rest. When the SVT occurs in association with an infusion/IV catheter, there is no recommendation for anticoagulation. [24] The 9 th edition of the American College of Chest Physicians guidelines recommends the use of prophylactic anticoagulation with either LMWH or fondaparinux, if there is at least 5 cm of thrombus in the superficial vein. Additional indications for anticoagulation include involvement above the knee, particularly close to the SFJ, involvement of GSV, prior history of VTE or SVT, malignancy, recent surgery, and in anyone with extensive/ severe symptoms of SVT. [24] The comparison of ARIXTRA™ in lower-limb superficial thrombophlebitis with placebo study proved the efficacy of fondaparinux (2.5 mg/day for 45 days) over placebo in reducing the risk of VTE, recurrent SVT, and extension of SVT. [25] There is currently no evidence of support the use of antiplatelet drugs in the management of SVT. [24] Anticoagulation can be done with oral VKAs, fondaparinux, or LMWH. A systematic review comparing various anticoagulant agents supports the use of fondaparinux in prophylactic doses for a duration of 45 days. [26] The SURPRISE trial showed that rivaroxaban 10 mg OD is not inferior to fondaparinux 2.5 mg OD for 45 days in terms of efficacy and is not associated with higher rates of major bleeding. [27] However, at this point, there is not enough evidence of recommending the routine use of direct thrombin inhibitors or factor Xa inhibitors in the treatment of SVT. [5, 26] Graduated compression therapy helps improve venous flow and local fibrinolytic activity. All patients should be mobilized along with compression therapy within the tolerance limits of pain. Compression therapy may be started with short-stretch bandages followed by support stockings if tolerated by the patient. [1, 5] cOncLUSiOnS SVT, though seemingly benign, has the potential for serious complications. It is imperative to promote awareness of this condition to be able to start accurate and adequate treatment. Prospective studies and registries are the way forward in our country.
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Surgery
Controversial. Ligation and stripping has been proposed in case of proximal extension of thrombus into the SFJ Also, for excision of vein segment if symptoms persist for >2 weeks [5] Indicated if there is a local abscess for incision and drainage
Topical therapy May help in local signs and symptoms Diclofenac gel, heparin local application [3] Only for symptomatic relief Antibiotics For local infection [1] NSAIDs: Nonsteroidal anti-inflammatory drugs, SVT: Superficial venous thrombosis, NOAC: Newer oral anticoagulant, UFH: Unfractionated heparin, LMWH: Low-molecular-weight heparin, SFJ: Saphenofemoral junction
